

## Special Issue

# Antimicrobials and Antimicrobial Resistance: Current and Future Prospects

### Message from the Guest Editor

*Dear Colleagues*, The World Health Organization (WHO) has declared that AMR is one of the top 10 global public health threats facing humanity. The misuse and overuse of antimicrobials are considered the main drivers of the development and spread of drug-resistant pathogens. In addition, lack of clean water and effective infection control measures lead to the further enumeration of microorganisms that are potentially resistant to different antimicrobials. Moreover, the direct and indirect economic losses associated with AMR are significant. We need to understand that without effective antimicrobials, the success of modern medicine varying from simple interventions (e.g., cesarean section) to complicated ones (major surgery, organ transplantations, etc.) is under increasing risk. Therefore, this Special Issue welcomes submissions related to different aspects of AMR, including epidemiology, surveillance, and analysis of consumption data. Submissions of effective interventions to combat AMR are especially welcome. Keywords: antibiotics; antimicrobial resistance; surveillance; epidemiology; consumption data

### Guest Editor

Prof. Dr. Roman Kozlov

Institute of Antimicrobial Chemotherapy, Smolensk State Medical University, 214019 Smolensk, Russia

### Deadline for manuscript submissions

closed (30 April 2022)



## Antibiotics

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.3  
CiteScore 7.3  
Indexed in PubMed



[mdpi.com/si/70383](https://mdpi.com/si/70383)

*Antibiotics*

MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[antibiotics@mdpi.com](mailto:antibiotics@mdpi.com)

[mdpi.com/journal/  
antibiotics](https://mdpi.com/journal/antibiotics)





# Antibiotics

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.3  
CiteScore 7.3  
Indexed in PubMed



[mdpi.com/journal/  
antibiotics](https://mdpi.com/journal/antibiotics)



## About the Journal

### Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

---

### Editor-in-Chief

Prof. Dr. Nicholas Dixon  
School of Chemistry and Molecular Bioscience, University of  
Wollongong, Wollongong, NSW 2522, Australia

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1  
(General Pharmacology, Toxicology and Pharmaceutics)